Spike Protein News and Research

RSS

An in-depth analysis of pathogenesis of SARS-CoV-2 and therapeutic options for COVID-19

Scientists discuss the pathogenic characteristics of SARS-CoV-2 and available therapeutic interventions for treating COVID-19.

3 Apr 2022

Groundbreaking collaborative work defines the risk of SARS-CoV-2 variants on immune protection

In a paper in the journal Nature, Los Alamos National Laboratory scientists Bette Korber, Hyejin Yoon, Will Fischer and James Theiler, among nearly 130 authors from institutions around the world, describe their groundbreaking collaborative work, "Defining the risk of SARS-CoV-2 variants on immune protection."

1 Apr 2022

Study identifies a new class of monoclonal antibodies that neutralize both alpha and beta coronaviruses

A team of international scientists has recently isolated and characterized pan-coronavirus neutralizing antibodies from individuals with pre-existing immunity against SARS-CoV-2.

1 Apr 2022

No evidence of SARS-CoV-2 in the U.K.'s wild deer population

A new study accepted for publication in the journal Transboundary and Emerging Diseases assesses the potential exposure of U.K. deer to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) since studies have shown the spill-over of SARS-CoV-2 infections to the Northern American white-tailed deer. If there is a spill-over, wild deer species can act as reservoirs of SARS-CoV-2 with the possibility of the emergence of new variants.

31 Mar 2022

NIH program provides a real-time risk assessment of variants of SARS-CoV-2

Faculty from the Departments of Microbiology, Medicine Genetics and Genomic Sciences, and Pathology and Molecular Cell-Based Medicine at the Icahn School of Medicine at Mount Sinai play key roles in a National Institutes of Health (NIH) program set up to provide a real-time risk assessment of variants of SARS-CoV-2, the virus that causes COVID-19. The program, called SARS-CoV-2 Assessment of Viral Evolution (SAVE) and described in a paper published March 31 in Nature, assesses how the variants might affect transmission, virulence, and resistance to both disease-induced (convalescent) and vaccine-induced immunity.

31 Mar 2022

The mucosal antibody response to SARS-CoV-2

Researchers determine mucosal SARS-CoV-2-specific antibody levels and their neutralizing effect in pediatric and adult patients.

31 Mar 2022

The evolution of the SARS-CoV-2 spike protein

Researchers discuss the evolution and mechanisms of mutations that have occurred in the spike protein of SARS-CoV-2.

31 Mar 2022

Study sheds light on the conformational dynamics of SARS-CoV-1 and SARS-CoV-2 spike proteins

New computational simulations of the behavior of SARS-CoV-1 and SARS-CoV-2 spike proteins prior to fusion with human cell receptors show that SARS-CoV-2, the virus that causes COVID-19, is more stable and slower changing than the earlier version that caused the SARS epidemic in 2003.

31 Mar 2022

Common coronavirus infections don't generate antibodies that effectively cross-react with SARS-CoV-2

Although SARS-CoV-2 has taken the world by storm, it's not the only coronavirus that can infect humans.

30 Mar 2022

Role of SARS-CoV-2 S1 subunit in severe COVID-19

A new study aimed to determine whether portions of the SARS-CoV-2 spike protein are capable of activating innate immune cells like Gal-3.

30 Mar 2022

Chemical in leafy greens could prevent infections by coronaviruses including SARS-CoV-2

Researchers discuss the use of the isothiocyanate sulforaphane for the treatment of both SARS-CoV-2 and HCoV-OC43 infections.

30 Mar 2022

Study analyzed several naturally-occurring amino acid variations found in the extended loop harboring the SARS-CoV-2 S1/S2 cleavage site

A recent study analyzed the polymorphisms in the SARS-CoV-2 spike proteins' S1/S2 subunits.

30 Mar 2022

Study investigates whether coinfection with multiple SARS-CoV-2 variants exists in COVID-19 patients

A new study shows that multiple variants of this virus may coinfect the same patient, using both genomic sequencing data and computational models.

30 Mar 2022

A ferritin nanoparticle candidate vaccine for COVID

In a recent study published on the bioRxiv* preprint server, the immunogenicity, and effectiveness of SARS-CoV-2 spike ferritin nanoparticle (SpFN) adjuvanted with aluminum hydroxide (AlOH3) or Army Liposomal Formulation QS-21 (ALFQ) in a cynomolgus macaque (CM) COVID-19 model was evaluated.

30 Mar 2022

SARS-CoV-2 nucleocapsid protein linked to COVID-19 severity

The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes respiratory coronavirus disease 2019 (COVID-19) triggered an unprecedented public health emergency. Human mobility patterns were fundamental to the spread of SARS-CoV-2 globally. The situation is particularly acute in a country like Saudi Arabia, which has seen more than 750,000 cases and over 9,000 deaths as of March 30th, 2022.

29 Mar 2022

Immunity against SARS-CoV-2 BA.1, BA.2, and BA.3 after three doses of BNT162b2 vaccine

A new study assesses the neutralization of three Omicron sublineages by BNT162b2-vaccinated sera collected one month after the third vaccine dose. A preprint version of the study is available on the bioRxiv* server while the article undergoes peer review.

29 Mar 2022

Furin inhibitors as potential therapies to combat SARS-CoV-2 and other diseases

Furin inhibitors as potential therapeutics for treating COVID-19 and other diseases, wherein furin is integral for their pathogenicity and progression.

29 Mar 2022

The different actions of CBD in SARS-CoV-2 infection

An article has described the role of cannabidiol as a potential inhibitor of hyperinflammation in SARS-CoV-2 infection.

29 Mar 2022

Algal metabolites as novel drugs against viruses

A new review article published in the Journal of Biotechnology has provided information on various nutraceutical metabolites extracted from algae.

29 Mar 2022

One year after severe COVID-19, T cells persist against SARS-CoV-2

In a recently published article in the journal eBioMedicine, scientists have demonstrated that critically ill coronavirus disease 2019 (COVID-19) patients are capable of generating durable memory T cell response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for more than one year after hospital discharge.

28 Mar 2022

Spike Protein News and Research

An in-depth analysis of pathogenesis of SARS-CoV-2 and therapeutic options for COVID-19

Groundbreaking collaborative work defines the risk of SARS-CoV-2 variants on immune protection

Study identifies a new class of monoclonal antibodies that neutralize both alpha and beta coronaviruses

No evidence of SARS-CoV-2 in the U.K.'s wild deer population

NIH program provides a real-time risk assessment of variants of SARS-CoV-2

The mucosal antibody response to SARS-CoV-2

The evolution of the SARS-CoV-2 spike protein

Study sheds light on the conformational dynamics of SARS-CoV-1 and SARS-CoV-2 spike proteins

Common coronavirus infections don't generate antibodies that effectively cross-react with SARS-CoV-2

Role of SARS-CoV-2 S1 subunit in severe COVID-19

Chemical in leafy greens could prevent infections by coronaviruses including SARS-CoV-2

Study analyzed several naturally-occurring amino acid variations found in the extended loop harboring the SARS-CoV-2 S1/S2 cleavage site

Study investigates whether coinfection with multiple SARS-CoV-2 variants exists in COVID-19 patients

A ferritin nanoparticle candidate vaccine for COVID

SARS-CoV-2 nucleocapsid protein linked to COVID-19 severity

Immunity against SARS-CoV-2 BA.1, BA.2, and BA.3 after three doses of BNT162b2 vaccine

Furin inhibitors as potential therapies to combat SARS-CoV-2 and other diseases

The different actions of CBD in SARS-CoV-2 infection

Algal metabolites as novel drugs against viruses

One year after severe COVID-19, T cells persist against SARS-CoV-2

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News